Hepatitis C News and Research

Latest Hepatitis C News and Research

WHO releases first-ever guidance for chronic hepatitis B treatment

WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year - most of them in low- and middle-income countries.

12 Mar 2015

Understanding strengths and weaknesses of hepatitis C viruses

Using a specially selected library of different hepatitis C viruses, a team of researchers led by Johns Hopkins scientists has identified tiny differences in the pathogens' outer shell proteins that underpin their resistance to antibodies.

12 Mar 2015

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit.

11 Mar 2015

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), a novel, long-acting, mono-pegylated interferon for the first line treatment of polycythemia vera.

11 Mar 2015

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Officials from the National Institutes of Health and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection.

9 Mar 2015

Women for Positive Action introduces new educational tool for women living with HIV

To mark International Women's Day (March 8, 2015), Women for Positive Action has launched a practical and informative new educational tool entitled 'Hepatitis and coinfection in women living with HIV'. Led by a global, multidisciplinary group of experts, Women for Positive Action is committed to addressing the specific concerns of women living with HIV.

6 Mar 2015

Biomarker for compilation of Risk Score for non-alcoholic steatohepatitis

40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in an affluent society. Currently, it is not possible to forecast the further course of the disease - right up to cirrhosis and cancer of the liver. Furthermore, an increased risk of heart attack and kidney damage exists. In future, this should become possible using a Risk Score with different biomarkers.

6 Mar 2015

Prime Therapeutics recognized with PBMI's 2015 Rx Innovation Award

Prime Therapeutics LLC received the Pharmacy Benefit Management Institute's 2015 Rx Innovation Award today in recognition of its innovative "Specialty Drug Watch List."

3 Mar 2015

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region.

26 Feb 2015

‘Most’ cirrhotic HBV patients benefit from adding adefovir to lamivudine

Response-guided addition of adefovir to lamivudine-based therapy not only maintains long-term viral suppression in Chinese chronic hepatitis B patients with compensated liver cirrhosis, research suggests, but also improves liver function.

23 Feb 2015

Mylan to distribute Sovaldi and Harvoni tablets in India for treatment of chronic hepatitis C

Mylan Inc. today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with Gilead Sciences, under which Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India.

23 Feb 2015

Betaretrovirus may infect patients with primary biliary cirrhosis

In a new study published in Alimentary Pharmacology & Therapeutics, researchers at the University of Alberta's Faculty of Medicine & Dentistry have shown that a betaretrovirus which resembles a mouse mammary tumor virus infects patients with the rare liver disease, primary biliary cirrhosis (PBC).

20 Feb 2015

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2014, including a summary of recent corporate highlights.

19 Feb 2015

IL-23 predicts PegIFN response in chronic HBV

High baseline serum levels of interleukin-23 can help to identify hepatitis B e antigen-positive chronic hepatitis B patients who are likely to respond to pegylated interferon treatment, a Chinese study indicates.

18 Feb 2015

TDF monotherapy ‘reasonable’ option in entecavir-resistant HBV

Researchers from the Republic of Korea have found that the efficacy of tenofovir disoproxil fumarate monotherapy is comparable to that of TDF plus entecavir in chronic hepatitis B patients with genotypic resistance to entecavir.

18 Feb 2015

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Long-term tenofovir disoproxil fumarate therapy is effective in Chinese patients with chronic hepatitis B virus infection who have relapsed after treatment with multiple nucleos(t)ide analogues, research suggests.

18 Feb 2015

Rutgers patient gets second chance at life following liver transplant

Mati Muñoz is 65 years old - filled with the enthusiastic energy that comes with a second chance at life. A decade ago, says Muñoz, who lives in Woodbridge Township, N.J., her liver was being destroyed by hepatitis C, a viral disease she believes she contracted as a girl in her native Cuba from a poorly sterilized needle used in a medical procedure.

17 Feb 2015

Report: Proposed SDGs may not achieve policy objectives without clearer, more measurable targets

The proposed UN Sustainable Development Goals (SDGs) - a universal set of goals to guide international development to 2030 - will struggle to achieve their stated policy objectives without clearer, more measurable targets, according to a new report released today by the International Council for Science and the International Social Science Council.

16 Feb 2015

Door-to-door campaing encourages people to get tested for hepatitis C and to get linked to care

In Philadelphia, as in many cities, neighborhoods with high rates of hepatitis C virus (HCV) often also have limited access to screening and treatment. A new study in the Journal of General Internal Medicine shows that when expert advocates made a focused effort in a medically underserved area, they were able to help vulnerable patients leap each of the many hurdles that often keep people out of care.

15 Feb 2015

Despite growing shortage of donor hearts, surgeons, transplant centers reject marginal hearts

Surgeons and transplant centers nationwide increasingly have rejected hearts donated for transplantation despite a growing need for them, according to a new study by researchers at the Stanford University School of Medicine.

12 Feb 2015

Hepatitis C News and Research

Latest Hepatitis C News and Research

WHO releases first-ever guidance for chronic hepatitis B treatment

Understanding strengths and weaknesses of hepatitis C viruses

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Women for Positive Action introduces new educational tool for women living with HIV

Biomarker for compilation of Risk Score for non-alcoholic steatohepatitis

Prime Therapeutics recognized with PBMI's 2015 Rx Innovation Award

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

‘Most’ cirrhotic HBV patients benefit from adding adefovir to lamivudine

Mylan to distribute Sovaldi and Harvoni tablets in India for treatment of chronic hepatitis C

Betaretrovirus may infect patients with primary biliary cirrhosis

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

IL-23 predicts PegIFN response in chronic HBV

TDF monotherapy ‘reasonable’ option in entecavir-resistant HBV

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Rutgers patient gets second chance at life following liver transplant

Report: Proposed SDGs may not achieve policy objectives without clearer, more measurable targets

Door-to-door campaing encourages people to get tested for hepatitis C and to get linked to care

Despite growing shortage of donor hearts, surgeons, transplant centers reject marginal hearts

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis C News and Research

Latest Hepatitis C News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in